Charles Schwab Investment Management Inc Neurocrine Biosciences Inc Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 725,178 shares of NBIX stock, worth $99.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

725,178

Previous 686,835 5.58%

Holding current value

$99.8 Million

Previous $90.5 Million 10.52%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$130.4 - $143.74 $5 Million - $5.51 Million	38,343 Added 5.58%	725,178 $100 Million
Q4 2023 Feb 06, 2024	BUY	$106.07 - $132.76 $6.74 Million - $8.44 Million	63,568 Added 10.2%	686,835 $90.5 Million
Q3 2023 Nov 08, 2023	BUY	$94.02 - $117.1 $1.72 Million - $2.15 Million	18,334 Added 3.03%	623,267 $70.1 Million
Q2 2023 Aug 09, 2023	BUY	$89.53 - $104.87 $1.84 Million - $2.15 Million	20,541 Added 3.51%	604,933 $57 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $1.73 Million - $2.26 Million	18,353 Added 3.24%	584,392 $59.2 Million

Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $2.67 Million - $3.18 Million	25,063 Added 4.63%	566,039 $67.6 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $733,939 - $859,784	7,975 Added 1.5%	540,976 $57.5 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $921,000 - $1.22 Million	12,152 Added 2.33%	533,001 $52 Million
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $813,903 - $1.07 Million	11,234 Added 2.2%	520,849 $48.8 Million
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $999,368 - $1.33 Million	12,547 Added 2.52%	509,615 $43.4 Million
Q3 2021 Nov 16, 2021	BUY	$86.18 - $99.03 $1.5 Million - $1.73 Million	17,419 Added 3.63%	497,068 $47.7 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $1.12 Million - $1.29 Million	12,579 Added 2.69%	479,649 $46.7 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $652,484 - $889,649	-7,451 Reduced 1.57%	467,070 $45.4 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $346,683 - $432,128	3,989 Added 0.85%	474,521 $45.5 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $774,088 - $1.09 Million	8,050 Added 1.74%	470,532 $45.2 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $889,445 - $1.36 Million	10,453 Added 2.31%	462,482 $56.4 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $792,560 - $1.2 Million	10,552 Added 2.39%	452,029 $39.1 Million
Q4 2019 Feb 07, 2020	BUY	$86.8 - $118.57 $730,856 - $998,359	8,420 Added 1.94%	441,477 $47.5 Million
Q3 2019 Nov 08, 2019	BUY	$83.82 - $101.5 $2.64 Million - $3.2 Million	31,520 Added 7.85%	433,057 $39 Million
Q2 2019 Aug 09, 2019	BUY	$72.24 - $91.27 $1.13 Million - $1.42 Million	15,588 Added 4.04%	401,537 $33.9 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $1.84 Million - $2.43 Million	26,503 Added 7.37%	385,949 $34 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $971,237 - $1.77 Million	14,216 Added 4.12%	359,446 $25.7 Million
Q3 2018 Nov 13, 2018	SELL	$98.88 - $125.85 $12.6 Million - $16 Million	-127,057 Reduced 26.9%	345,230 $42.4 Million
Q2 2018 Aug 08, 2018	BUY	$75.3 - $105.99 $2.47 Million - $3.47 Million	32,769 Added 7.46%	472,287 $46.4 Million
Q1 2018 May 07, 2018	BUY	$75.88 - $92.43 $2.28 Million - $2.77 Million	29,996 Added 7.32%	439,518 $36.5 Million
Q4 2017 Jan 17, 2018	BUY	$58.53 - $77.59 $1.51 Million - $2 Million	25,834 Added 6.73%	409,522 $31.8 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $18.4 Million - $23.5 Million	383,688	383,688 $23.5 Million

Others Institutions Holding NBIX

# of Institutions

628

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Neurocrine Biosciences Inc Transaction History